10. Subchronic toxicity assessments of silymax complex capsules in wistar rats
Main Article Content
Abstract
It has recently become obvious that the prevalence of adults with diagnosed liver diseases has been rapidly increasing in Vietnam, as well as other countries, over the past two decades. There has been a current trend for researchers to discover new natural ingredients which were safe and still effective in the treatment of liver diseases. Silymax Complex was a herbal-derived product (Carduus marianus, Extractum Herba Phyllanthi urinariae, Extractum Fructus Schisandrae, Extractum Herba Adenosmatis caerulei and Curcuma longa L.) used as an oral medication. So far, the safety of this product has not been reported in Vietnam. Thus, this study was designed to assess the subchronic toxicity of Silymax Complex capsules in Wistar rats. The method used in this study followed the guidance of World Health Organization and Organization for Economic Co-operation and Development in rats with 2 oral doses of 316.8 mg/kg b.w/day and 950.4 mg/kg b.w/day for 12 consecutive weeks. As a result, Silymax Complex capsules caused no significant changes in general condition, hematological indexes, hepato-renal functions and microscopic images of livers and kidneys. In light of our findings, Silymax Complex capsules did not cause subchronic toxicity in experimental rats. Moreover, this also revealed partly the safety of Silymax Complex capsules in clinical practice.
Article Details
Keywords
Silymax Complex capsules, subchronic toxicity, Wistar rats
References
2. Kockerling D, Nathwani R, Forlano R, et al. Current and future pharmacological therapies for managing cirrhosis and its complications. World J Gastroenterol. 2019 Feb 28; 25(8): 888-908.
3. Guite NT. International Protocol and Indigenous Knowledge on Medicine and Health Care: An overview. The Asian Man. 2010; 1(4): 01 - 12.
4. World Health Organization, Global report on traditional and complementary medicine. 2019.
5. Venkatasubbu GD, Ramasamy S, Gaddam PR, et al. Acute and subchronic toxicity analysis of surface modified paclitaxel attached hydroxyapatite and titanium dioxide nanoparticles. International Journal of Nanomedicine. 2015; 10: 137-148.
6. De Jong WH, Carraway JW, Geertsma RE. In vivo and in vitro testing for the biological safety evaluation of biomaterials and medical devices. Biocompatibility and Performance of Medical Devices. 2012; 120-158.
7. OECD, Guidelines for the testing of chemicals repeated dose oral toxicity study in rodents, Environmental Health and Safety Monograph Series on Testing and Assesment No 407. 2008.
8. World Health Organization. Guidelines for Assessing Quality of Herbal Medicines With Reference to Contaminants and Residues, Geneva. 2007.
9. Litchfield J T& Wilcoxon F A. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 1949; 96: 99-113.
10. World Health Organization. Working group on the safety and efficacy of herbal medicine. Report of regional office for the western pacific of the World Health Organization. 2000.
11. National Research Council. Toxicity testing for assessing environmental agents. Interim Report. Washington, DC, USA: National Academies Press. 2006.
12. Olson H, Betton G, Robinson D et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory Toxicology and Pharmacology. 2000; 32(1): 56–67.
13. Vahid Soleimani, Parisa Sadat Delghandi, Seyed Adel Moallem et al. Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review. Phytotherapy Research. 2019; 33: 1627–1638.
14. Murugan S, Solanki H, Purusothaman D, et al. Safety Evaluation of Standardized Extract of Curcuma longa (NR-INF-02): A 90-Day Subchronic Oral Toxicity Study in Rats. Biomed Res Int. 2021 Jul 14; 2021: 6671853.